
LH Stock Forecast & Price Target
LH Analyst Ratings
Bulls say
Laboratory Corp. of America (Labcorp Holdings) is positioned for a strong growth trajectory, with the Diagnostics segment reporting a robust year-over-year revenue growth of 7.9%, culminating in $2.52 billion for the quarter. Additionally, the company has projected revenue growth for 2024 between $12.9 billion to $13.1 billion, representing an increase of 6.4% to 7.5%, which reflects a significant uptick from historical averages. The improved adjusted operating margin of 15.2%, supported by organic growth and efficiencies from LaunchPad, further reinforces the company's operational strength and financial stability.
Bears say
Labcorp Holdings has lowered its revenue guidance for the upcoming fiscal year, projecting a modest growth of only 3.7% to 5.0%, which reflects a concerning trend in the company’s financial health. The impact of pricing cuts under the PAMA regulations and significant challenges in capturing synergies from acquisitions are expected to contribute to downward pressure on profit margins, further complicating the company's growth outlook. Additionally, the company's biopharma revenue growth of 1.1% year-over-year fell short of expectations, highlighting underlying operational difficulties and intensified competition within the market.
This aggregate rating is based on analysts' research of Labcorp Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
LH Analyst Forecast & Price Prediction
Start investing in LH
Order type
Buy in
Order amount
Est. shares
0 shares